Dose Optimization for Anticancer Drug
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".
Deadline for manuscript submissions: closed (10 July 2021) | Viewed by 276
Special Issue Editor
Interests: anticancer drug; biopharmaceutics; dose optimization; exposure-response relationship; clinical pharmacokinetics; pharmacodynamics
Special Issue Information
Dear Colleagues,
The administration of the optimal doses of anticancer drugs is particularly important for the successful treatment of cancer diseases. For cytotoxic drugs with a narrow therapeutic index, the standard approach in finding an appropriate dose has been based on identifying the maximum tolerated dose in clinical trials. Such an approach does not appear to be appropriate for targeted anticancer agents whose doses need to be optimized not simply based on toxicity but rather efficacy predictions. However, the dose-response relationship of any drug is not easy to predict in cancer patients because of highly variable pathophysiological conditions.
To date, numerous approaches have been exercised in optimizing the doses of anticancer drugs using sophisticated in vitro, in vivo, clinical, and in silico tools. The approaches account for but are not limited to biopharmaceutic, demographic, environmental, pharmacogenomic, pharmacologic, and pathophysiologic characteristics of the drugs and patients. Hence, the aim of this Special Issue of Pharmaceutics is to share the up-to-date approaches in and the expert opinions on the dose optimization for anticancer drugs. The editors welcome not only primary research but also review manuscripts for publication from diverse perspectives.
Dr. Jangik Ike Lee
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
